Speaker illustration

Professor Alec Vahanian

University Paris-Descartes, Paris (France)

Member of:

European Society of Cardiology

I am Emeritus Professor at university of Paris

TAVI Update: Latest evidence leads to growing confidence in patient treatment

Event: ESC Congress 2021 - The Digital Experience

Topic: Valvular Heart Disease

Session type: Satellite Symposium

Thumbnail

Registries on Valve

Event: ESC Congress 2021 - The Digital Experience

Topic: Valvular Heart Disease

Session type: Late-Breaking Science

Thumbnail

2021 ESC/EACTS Guidelines for the management of valvular heart disease

Event: ESC Congress 2021 - The Digital Experience

Topic: Valvular Heart Disease

Session type: New ESC Guidelines

Thumbnail

How should I treat a patient with severe aortic stenosis and coronary artery disease at low surgical risk?

Event: ESC Congress 2021 - The Digital Experience

Topic: Valvular Heart Disease

Session type: How Should I Treat?

Thumbnail

Congress committee e-posters choice in valvular

Event: ESC Congress 2021 - The Digital Experience

Topic: Valvular Heart Disease

Session type: Congress Committee e-posters Choice

Thumbnail

Controversies in Aortic Stenosis: Is TAVI the Preferred Therapy for Low-Risk Patients?

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Treatment

Session type: Debate Session

Thumbnail

Controversies in valvular heart disease

Event: ESC CONGRESS 2019

Topic: Treatment

Session type: Debate Session

Thumbnail

Guidelines in Daily Practice - Valvular Heart Disease

Event: ESC CONGRESS 2019

Topic: Valvular Heart Disease

Session type: Case-Based Session

Thumbnail

The European Heart Journal’s advances in heart failure and valvular heart disease: the year in cardiology

Event: ESC Congress 2018

Topic: Other

Session type: Special Session

Thumbnail

Aortic stenosis treatments? I know it all! – You will be surprised….

Event: ESC Congress 2018

Topic: Valvular Heart Disease

Session type: Satellite Symposium

Thumbnail

This platform is supported by

logo Novo Nordisk